Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Trial of GDC-0941 with Carboplatin/Paclitaxel ± Bevacizumab in Advanced or Recurrent Non-Small Cell Lung Cancer
2011-002893-21Phase 2Terminated
- Sponsor
- Genentech
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pictilisib in non-small cell lung cancer (NSCLC) (4 arms), sponsored by Genentech. Primary endpoints: Progression-Free Survival and Safety and Tolerability. Started Feb 2012; status: terminated.
02
Drugs
pictilisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-002893-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002893-21.